Antipsychotic polypharmacy – confusion reigns. Psychiatrist
2010; 34: 41–3.
Langan, J, Shajahan, P.
Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist
2010; 34: 58–62.
Fleischhacker, WW, Heikkinen, T, Olie, JP, Landsberg, W, Dewaele, P, McQuade, RD, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16 week double-blind study. Eur Psychiatry
2008; 2: s114–5.
Tungaraza, TE, Gupta, S, Jones, J, Poole, R, Slegg, G.
Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist
2010; 34: 44–6.
Achim, AM, Maziade, M, Raymond, E, Olivier, D, Mérette, C, Roy, MA. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull
2009 Dec 3 [epub ahead of print], doi: 10.1093/schbul/sbp148
Dernovsek, MZ, Sprah, L.
Comorbid anxiety in patients with psychosis. Psychiatr Danub
2009; 21 (suppl 1): 43–50.
Sharma, VK, Lepping, P, Cummins, AG, Copeland, JR, Parhee, R, Mottram, P.
The Global Mental Health Assessment Tool – Primary Care Version (GMHAT/PC). Development, reliability and validity. World Psychiatry
2004; 3: 115–9.
Mortimer, AM. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr Dis Treat
2009; 5: 267–77.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009; 373: 31–41.
Karunakaran, K, Tungaraza, TE, Harborne, GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
2007; 21: 453–6.